Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | GAA | P10253 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4538229 | 0.80 | RECQL (0.60) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL2615402 | 0.79 | GAA (0.65) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL6406779 | 0.78 | RAB9A (0.60) | RAB9AKDM4EHPGDALDH1A1MAPT | |
| SCHEMBL1434288 | 0.76 | GAA (0.66) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL1764592 | 0.76 | RAB9A (0.61) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL2405184 | 0.76 | RAB9A (0.71) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL9528793 | 0.76 | KDM4E (0.63) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL1764515 | 0.76 | RAB9A (0.64) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL17790891 | 0.76 | GAA (0.61) | RAB9AKDM4EGAAPOLBHTT | |
| SCHEMBL9728319 | 0.76 | GAA (0.61) | RAB9AKDM4EGAAPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| EP-2544679-B1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2018-10-23 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | OMEROS CORPORATION | 2017-06-01 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434707-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2016-09-06 | — | — | US | disclosed |
| US-9102643-B2 | PDE10 inhibitors and related compositions and methods | OMEROS CORPORATION (US) | 2015-08-11 | — | — | US | disclosed |
| WO-2009021946-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009021758-A1 | ARYLSULFONAMIDES HAVING AN ANALGESIC EFFECT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | WO | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| EP-2025675-A1 | Arylsulfonamides with analgetic activity | Boehringer Ingelheim International GmbH (DE) | 2009-02-18 | — | — | EP | disclosed |
| WO-2008022945-A1 | ARYL SULFONAMIDES WITH AN ANALGESIC ACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-28 | — | — | WO | disclosed |
| US-5607953-A | ANTIISCHEMIC AGENTS | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| EP-0344577-B1 | Butenoic or propenoic acid derivatives | EISAI CO LTD (JP) | 1996-10-09 | — | — | EP | disclosed |
| US-5382595-A | Antiischemic agents | EISAI CO., LTD. (JP) | 1995-01-17 | — | — | US | disclosed |
| US-5177089-A | Antiischemic agent, vasodilator | EISAI CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0344577-A2 | Butenoic or propenoic acid derivatives | Eisai Co., Ltd. (JP) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106516-B2 | PDE10 inhibitors and related compositions and methods | PDE10A, PDE9A, PDE7A | RAB9A 89/4885KDM4E 2629/4885GAA 64/4885 |
| US-20170152238-A1 | PDE10 INHIBITORS AND RELATED COMPOSITIONS AND METHODS | PDE10A, PDE9A, PDE7A | RAB9A 89/4885KDM4E 2629/4885GAA 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.